Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Acrux Limited ( (AU:ACR) ) just unveiled an update.
Acrux Limited has announced the issuance of 3,714,284 fully paid ordinary shares to its directors, following shareholder approval at an Extraordinary General Meeting earlier in February. These Director Placement Shares were issued under the same terms and conditions as previous shares from the Share Placement and Share Purchase Plan announced in December 2024. The company has complied with the relevant provisions of the Corporations Act and confirms that there is no excluded information related to this issuance.
More about Acrux Limited
Acrux is a specialty pharmaceutical company that focuses on developing and commercializing topically applied pharmaceutical products. With 25 years of experience, the company has marketed several products globally through licensees, particularly emphasizing the United States market. Acrux is involved in formulating and developing a range of topical generic products, utilizing its skilled workforce, advanced laboratories, and GMP manufacturing suite to deliver affordable products. The company is open to collaboration and is well-positioned for commercial partnerships and product development opportunities.
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $7.86M
For detailed information about ACR stock, go to TipRanks’ Stock Analysis page.
